SPONSOR
Shanghai Pulmonary Hospital, Shanghai, China
Total Trials
5
Recruiting
5
Phases
Phase 2
Conditions studied: Thymic CarcinomaExtensive-stage Small Cell Lung Cancer (ES-SCLC)Thoracic NeoplasmsLung NeoplasmsLung DiseasesIdiopathic Pulmonary FibrosisProgressive Pulmonary FibrosisEGFR-mutant Non-small Cell Lung CancerPotentially ResectableLung Cancer
Shanghai Pulmonary Hospital, Shanghai, China is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including Thymic Carcinoma, Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms, Lung Neoplasms.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shanghai Pulmonary Hospital, Shanghai, China
How many clinical trials has Shanghai Pulmonary Hospital, Shanghai, China sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by Shanghai Pulmonary Hospital, Shanghai, China, of which 5 are actively recruiting participants. These trials cover conditions including Thymic Carcinoma, Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shanghai Pulmonary Hospital, Shanghai, China research focus on?
Shanghai Pulmonary Hospital, Shanghai, China clinical trials span Thymic Carcinoma, Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms, Lung Neoplasms, Lung Diseases, and additional conditions. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shanghai Pulmonary Hospital, Shanghai, China clinical trial?
To participate in a Shanghai Pulmonary Hospital, Shanghai, China trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shanghai Pulmonary Hospital, Shanghai, China trials with current recruitment status updated daily.
Clinical Trials by Shanghai Pulmonary Hospital, Shanghai, China
NCT06019468 Phase 2
Recruiting
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
Thymic Carcinoma
NCT06758700 Phase 2
Recruiting
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
NCT07820254
Recruiting
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
Idiopathic Pulmonary Fibrosis
NCT07323056 Phase 2
Recruiting
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
EGFR-mutant Non-small Cell Lung Cancer
NCT05857800
Recruiting
Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment
Lung Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology